William Blair Investment Management LLC acquired a new position in shares of AstraZeneca Plc (NYSE:AZN – Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 557,483 shares of the company’s stock, valued at approximately $90,809,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. Allworth Financial LP lifted its stake in AstraZeneca by 313.0% in the 3rd quarter. Allworth Financial LP now owns 33,413 shares of the company’s stock valued at $5,395,000 after acquiring an additional 25,322 shares in the last quarter. GKV Capital Management Co. Inc. grew its stake in shares of AstraZeneca by 14.8% during the 3rd quarter. GKV Capital Management Co. Inc. now owns 12,905 shares of the company’s stock worth $2,100,000 after acquiring an additional 1,660 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of AstraZeneca by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 11,501,748 shares of the company’s stock worth $1,857,187,000 after acquiring an additional 355,456 shares in the last quarter. Legacy Trust bought a new position in shares of AstraZeneca during the 3rd quarter worth approximately $254,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of AstraZeneca by 0.9% in the third quarter. Russell Investments Group Ltd. now owns 2,052,004 shares of the company’s stock valued at $334,070,000 after purchasing an additional 18,417 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Stock Performance
Shares of AZN stock opened at $184.66 on Monday. The stock has a market cap of $286.40 billion, a P/E ratio of 26.12, a P/E/G ratio of 1.43 and a beta of 0.24. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.01 and a quick ratio of 0.79. The company has a fifty day moving average price of $168.82 and a two-hundred day moving average price of $180.20. AstraZeneca Plc has a one year low of $153.41 and a one year high of $212.71.
AstraZeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings data on Saturday, October 31st. The company reported $2.79 EPS for the quarter, beating analysts’ consensus estimates of $2.60 by $0.19. The company had revenue of $16.21 billion during the quarter, compared to the consensus estimate of $16 billion. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The company’s quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter last year, the firm posted $2.38 EPS. As a group, equities analysts predict that AstraZeneca Plc will post 10.22 EPS for the current year.
Analyst Ratings Changes
A number of analysts have recently issued reports on the stock. Deutsche Bank upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, September 15th. Nordea Equity Research upgraded shares of AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Royal Bank Of Canada started coverage on shares of AstraZeneca in a research report on Tuesday, September 8th. They issued an “outperform” rating for the company. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, October 6th. Finally, Weiss Ratings upgraded shares of AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 26th. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $206.67.
Read Our Latest Analysis on AstraZeneca
AstraZeneca Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Featured Articles
- Five stocks we like better than AstraZeneca
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
